Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of OPN305 for prevention of delayed graft function after high-risk kidney transplantation
NL-OMON39887Phase 2Active, not recruiting
- Sponsor
- Opsona Therapeutics
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tomaralimab in delayed graft function (DGF) (6 arms), sponsored by Opsona Therapeutics. Primary endpoints: TLR2 receptor occupancy and Incidence of delayed graft function by day 7. Started Sep 2013; status: active, not recruiting.
02
Drugs
tomaralimab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NL-OMON39887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39887.